BIOMERICA INC (BMRA)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$1.680.00%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 25, 2026

What could strengthen or challenge BIOMERICA INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-11-30
Revenue	—	3.63M
EPS	—	-1.2
Annual ending 2027-05-31
Revenue	—	7.41M
EPS	—	-1.36
Annual ending 2028-05-31
Revenue	—	5.96M
EPS	—	-1.28

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
M&A and capital moves support growth	A supporting condition in BIOMERICA INC's published investment case. The stated target is M&A leads to revenue or profit improvement.	Intact	M&A fails to improve revenue or profit within 1 year	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 25, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating income improves toward break-even	Biomerica aims to improve operating income and grow revenue.	Broken	Operating loss worsens or stays below -$1.3M next year	Operating income: $-1.227M FY2027-Q1; GAAP. Published target: Operating loss narrows toward $0. Target period is not explicitly aligned with this observation. Source published Oct 15, 2026-1,227,000 USD · source valueSource reportLast status assessment Oct 25, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Aug 31, 2026 Source: company_financial_results. Reference: 81364c67-1205-48cb-af51-95b5a0a7ece4. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth stabilizes or improves	A primary condition in BIOMERICA INC's published investment case. The stated target is >=0% YoY revenue growth.	Broken	YoY revenue growth falls below 0% next year	Revenue growth: -8.33% FY2027-Q1; GAAP. Published target: >=0% YoY revenue growth. Target period is not explicitly aligned with this observation. Source published Oct 15, 2026-8.333333 percent · calculatedSource reportLast status assessment Oct 25, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Aug 31, 2026 Source: company_financial_results. Reference: 81364c67-1205-48cb-af51-95b5a0a7ece4. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-05-31 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-09-04	Unavailable	Unavailable	1 / 1
2026-09-05	Unavailable	Unavailable	1 / 1
2026-09-06	Unavailable	Unavailable	1 / 1
2026-09-07	Unavailable	Unavailable	1 / 1
2026-09-08	Unavailable	Unavailable	1 / 1
2026-09-09	Unavailable	Unavailable	1 / 1
2026-09-10	Unavailable	Unavailable	1 / 1
2026-09-11	Unavailable	Unavailable	1 / 1
2026-09-12	Unavailable	Unavailable	1 / 1
2026-09-13	Unavailable	Unavailable	1 / 1
2026-09-14	Unavailable	Unavailable	1 / 1
2026-09-15	Unavailable	Unavailable	1 / 1
2026-09-16	Unavailable	Unavailable	1 / 1
2026-09-17	Unavailable	Unavailable	1 / 1
2026-09-18	Unavailable	Unavailable	1 / 1
2026-09-19	Unavailable	Unavailable	1 / 1
2026-09-20	Unavailable	Unavailable	1 / 1
2026-09-21	Unavailable	Unavailable	1 / 1
2026-09-22	Unavailable	Unavailable	1 / 1
2026-09-23	Unavailable	Unavailable	1 / 1
2026-09-24	Unavailable	Unavailable	1 / 1
2026-09-25	Unavailable	Unavailable	1 / 1
2026-09-26	Unavailable	Unavailable	1 / 1
2026-09-27	Unavailable	Unavailable	1 / 1
2026-09-28	Unavailable	Unavailable	1 / 1
2026-09-29	Unavailable	Unavailable	1 / 1
2026-09-30	Unavailable	Unavailable	1 / 1
2026-10-01	Unavailable	Unavailable	1 / 1
2026-10-02	Unavailable	Unavailable	1 / 1
2026-10-03	Unavailable	Unavailable	1 / 1
2026-10-04	Unavailable	Unavailable	1 / 1
2026-10-05	Unavailable	Unavailable	1 / 1
2026-10-06	Unavailable	Unavailable	1 / 1
2026-10-07	Unavailable	Unavailable	1 / 1
2026-10-08	Unavailable	Unavailable	1 / 1
2026-10-09	Unavailable	Unavailable	1 / 1
2026-10-10	Unavailable	Unavailable	1 / 1
2026-10-11	Unavailable	Unavailable	1 / 1
2026-10-12	Unavailable	Unavailable	1 / 1
2026-10-13	Unavailable	Unavailable	1 / 1
2026-10-14	Unavailable	Unavailable	1 / 1
2026-10-15	Unavailable	Unavailable	1 / 1
2026-10-16	Unavailable	Unavailable	1 / 1
2026-10-17	Unavailable	Unavailable	1 / 1
2026-10-18	Unavailable	Unavailable	1 / 1
2026-10-19	Unavailable	Unavailable	1 / 1
2026-10-20	Unavailable	Unavailable	1 / 1
2026-10-21	Unavailable	Unavailable	1 / 1
2026-10-22	Unavailable	Unavailable	1 / 1
2026-10-23	Unavailable	Unavailable	1 / 1
2026-10-24	Unavailable	Unavailable	1 / 1
2026-10-25	Unavailable	Unavailable	1 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Monthly analyst history is unavailable.

0 upgrades0 downgrades0 maintains

Recent actions · Sep 26–Oct 25 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 26, 2026–Oct 25, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

M&A and capital moves support growthQualitative condition
Operating income improves toward break-evenPublished status: Broken
Revenue growth stabilizes or improvesPublished status: Broken

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-49.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

BIOMERICA INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making small-cap business rather than an established earnings compounder. The long-term thesis is in a watch state: recent results have lagged its industry cohort, while the available evidence does not show a fresh break in the thesis.

What's priced into BIOMERICA INC

BMRA screens cheap versus peers, but valuation-model confidence is low and the expectations gap is strongly negative. The priced-in assessment is tagged justified, with no fragility gates triggered, so the evidence does not point to a clear mismatch between expectations and the business setup.

What the fundamentals likely do

Over the near term, improving operating income and revenue growth remain management priorities to watch, and recent quarters have included misses. The next-quarter miss risk is elevated; the private placement and equity sales also make capital allocation worth monitoring. Over the multi-year view, the Healthcare sector backdrop is a tailwind, but it does not resolve BMRA’s company-level execution risks.

What BIOMERICA INC hinges on

The thesis depends on whether BMRA can improve revenue growth and operating income while managing capital allocation. A weakening jobs report could add pressure through recession concerns, while continued earnings strength and higher guidance from ABT, MDT, and SYK could support the sector backdrop. Misses or lower guidance from those bellwethers could weaken that support.